Astragaloside II enhanced sensitivity of ovarian cancer cells to cisplatin via triggering apoptosis and autophagy

Author:

Zhang Lijia1,Liu Ye2,Lei Xue3,Liu Xiaowai3,Sun Heng4,Liu Songjiang4ORCID

Affiliation:

1. Ethics Committee Office First Affiliated Hospital, Heilongjiang University of Chinese Medicine Heilongjiang Harbin China

2. Department of Intensive Care Unit First Affiliated Hospital, Heilongjiang University of Chinese Medicine Harbin Heilongjiang China

3. Department of Clinical Specialty of Integrated Traditional Chinese and Western Medicine Graduate School, Heilongjiang University of Chinese Medicine Harbin Heilongjiang China

4. Department of Oncology First Affiliated Hospital, Heilongjiang University of Chinese Medicine Harbin Heilongjiang China

Abstract

AbstractCisplatin (DDP) based chemotherapy occurs a reduced therapeutic effect on the later treatment of ovarian cancer (OC) due to DDP resistance. Astragaloside II (ASII), a natural product extracted from Radix Astragali, has shown promising anticancer effects. However, the effects of ASII on OC have not been clarified. In this study, we found that ASII inhibited cell growth and promoted cell apoptosis of DDP‐resistant OC cells in vitro and in vivo. Further study showed that ASII downregulated multidrug resistance‐related protein MDR1 and cell cycle‐related protein Cyclin D1 and PCNA, and also upregulated apoptosis‐related protein leaved PRAP and cleaved caspase‐3. In addition, ASII induced autophagy, characterized by upregulation of LC3II expression, downregulation of p62 expression, and elevation of LC3 punctuation, may be associated with inhibition of the AKT/mTOR signaling pathway. Moreover, the messenger RNA‐sequencing was used to identify potential molecules regulated by ASII. In conclusion, these findings indicated that ASII increased sensitivity of DDP in the treatment of OC.

Publisher

Wiley

Subject

Cell Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3